Study on Physiotherapy for Parkinson’s Disease

Overview of Parkinson’s Disease

A recent study published in *Lancet Neurology* examined the effectiveness of specialized physiotherapy compared to standard physiotherapy in managing Parkinson’s disease. This neurodegenerative disorder primarily impacts dopamine-producing neurons in the brain. In the United States, approximately 60,000 individuals are diagnosed with Parkinson’s disease annually, with a global prevalence affecting around 10 million people. Despite ongoing research, the precise cause of Parkinson’s remains elusive, and existing medications only alleviate symptoms rather than cure the disease. Common symptoms include tremors, reduced movement, gait disturbances, balance issues, difficulties with speech, and sleep problems. The disease can be challenging to diagnose, as early symptoms may be mistaken for normal aging.

Management of Parkinson’s Disease

Management strategies for Parkinson’s disease typically focus on pharmacological treatments aimed at increasing dopamine levels. The primary medication used is Levodopa, often combined with Carbidopa to mitigate side effects. In addition to medication, physiotherapy, occupational therapy, and speech therapy play crucial roles in patient management.

Challenges in Parkinson’s Disease Care

Despite the growing global incidence of Parkinson’s, many healthcare professionals lack specialized training in its management. This gap was recognized by the Dutch clinical community, leading to the establishment of the ParkinsonNet (PN) program in 2004. This program creates an integrated network of specially trained physical therapists and healthcare providers focused on delivering tailored care to Parkinson’s patients.

Research Study Design

Study Parameters

The study conducted over three years, from January 1, 2013, to December 31, 2015, evaluated more than 4,000 patients through a medical claims database. The primary endpoint measured the proportion of patients experiencing complications related to Parkinson’s disease, such as fractures or injuries. Other factors assessed included physiotherapist caseload, the number of physiotherapy sessions, and associated treatment costs.

Findings on Specialized Physiotherapy

The findings, published in *Lancet Neurology*, indicated a significant need for transitioning patients from standard physiotherapy to specialized physiotherapy. Patients receiving care from specialized physiotherapists experienced fewer Parkinson-related complications and incurred approximately 400 euros less in treatment costs compared to those who attended general physiotherapy sessions. Furthermore, patients treated by specialized therapists required fewer sessions, resulting in reduced overall hospital costs by about 500 euros. The mortality risk for patients in the specialized group was also significantly lower.

Implications of the Study

Recommendations for Clinical Practice

The study reinforces earlier research supporting the effectiveness of the ParkinsonNET program. The authors advocate for clinicians to refer patients to this specialized network, as healthcare providers within the network typically manage a higher volume of Parkinson’s cases, enhancing their ability to meet patients’ specific needs.

Economic Considerations

The study’s data aligns with findings from KPMG, which reported savings of 640 euros a decade ago for patients receiving specialized care. Overall, the research emphasizes the superior quality of care provided through the ParkinsonNET network and highlights the economic benefits of such specialized programs. Given the substantial and increasing economic burden of Parkinson’s disease, promoting tailored care initiatives for neurodegenerative disorders is essential within the clinical community.

Author Information

Written by Vinayak Khattar, Ph.D., M.B.A.

Reference

Ypinga, J. H. L., de Vries, N. M., Boonen, L., Koolman, X., Munneke, M., Zwinderman, A. H., & Bloem, B. R. (2017). Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. *Lancet Neurol*. doi:10.1016/S1474-4422(17)30406-4